- Home
- HRMY
as 07-26-2024 4:00pm EST
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | PLYMOUTH MEETING |
| Market Cap: | 1.8B | IPO Year: | 2020 |
| Target Price: | $41.67 | AVG Volume (30 days): | 416.4K |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.31 | EPS Growth: | -25.48 |
| 52 Week Low/High: | $18.61 - $39.27 | Next Earning Date: | 08-06-2024 |
| Revenue: | $617,511,000 | Revenue Growth: | 30.92% |
| Revenue Growth (this year): | 24.4% | Revenue Growth (next year): | 18.24% |
Stock Insider Trading Activity of Harmony Biosciences Holdings Inc. (HRMY)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Dierks Jeffrey | HRMY | CHIEF COMMERCIAL OFFICER | Mar 15 '24 | Sell | $32.00 | 11,979 | $383,328.00 | 0 | SEC Form 4 |
| Dierks Jeffrey | HRMY | CHIEF COMMERCIAL OFFICER | Mar 8 '24 | Sell | $32.00 | 194 | $6,208.00 | 0 | SEC Form 4 |
Latest Harmony Biosciences Holdings Inc. News
HRMY Breaking Stock News: Dive into HRMY Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) Stock Is Going Strong: Is the Market Following Fundamentals?
Argus Research
3 days ago
HRMY: Lowering target price to $35.00
PR Newswire
3 days ago
HARMONY BIOSCIENCES TO REPORT SECOND QUARTER 2024 FINANCIAL RESULTS ON AUGUST 6, 2024
Zacks
4 days ago
HRMY or REGN: Which Is the Better Value Stock Right Now?
Zacks
7 days ago
Wall Street Analysts See a 32.82% Upside in Harmony Biosciences (HRMY): Can the Stock Really Move This High?
Zacks
9 days ago
Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?
Argus Research
10 days ago
HRMY: What does Argus have to say about HRMY?
Zacks
10 days ago
MannKind Corporation (MNKD) Hit a 52 Week High, Can the Run Continue?
Compare HRMY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HRMY Harmony Biosciences Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.